Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Caribou Biosciences (CRBU) Leases (2022 - 2025)

Caribou Biosciences has reported Leases over the past 4 years, most recently at $17.7 million for Q4 2025.

  • Quarterly Leases fell 11.69% to $17.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.7 million through Dec 2025, down 11.69% year-over-year, with the annual reading at $17.7 million for FY2025, 11.69% down from the prior year.
  • Leases was $17.7 million for Q4 2025 at Caribou Biosciences, up from $16.0 million in the prior quarter.
  • Over five years, Leases peaked at $25.7 million in Q1 2022 and troughed at $16.0 million in Q3 2025.
  • The 4-year median for Leases is $21.9 million (2023), against an average of $21.5 million.
  • Year-over-year, Leases dropped 7.9% in 2023 and then fell 22.11% in 2025.
  • A 4-year view of Leases shows it stood at $24.2 million in 2022, then fell by 8.45% to $22.2 million in 2023, then decreased by 9.8% to $20.0 million in 2024, then decreased by 11.69% to $17.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Leases are $17.7 million (Q4 2025), $16.0 million (Q3 2025), and $16.5 million (Q2 2025).